Loading…
Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis
In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed. Plasma was obtained from healthy subject...
Saved in:
Published in: | Arthritis research & therapy 2018-09, Vol.20 (1), p.211-211, Article 211 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423 |
---|---|
cites | cdi_FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423 |
container_end_page | 211 |
container_issue | 1 |
container_start_page | 211 |
container_title | Arthritis research & therapy |
container_volume | 20 |
creator | Szeremeta, Anna Jura-Półtorak, Agnieszka Koźma, Ewa Maria Głowacki, Andrzej Kucharz, Eugeniusz Józef Kopeć-Mędrek, Magdalena Olczyk, Krystyna |
description | In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed.
Plasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits.
Total sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels.
Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA. |
doi_str_mv | 10.1186/s13075-018-1711-z |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c9ba23ff973b4498a6cb5da2793e566f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c9ba23ff973b4498a6cb5da2793e566f</doaj_id><sourcerecordid>2108777939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423</originalsourceid><addsrcrecordid>eNpdkk1uFDEQhVsIRELgAGyQJTZsHNr_7Q0SihISKYJNWFvVbnvGo-72YLsTJbfiIpwJTyZECSuXXO99qiq9pnlP2mNCOvk5E9YqgVvSYaIIwXcvmkPCVYclk_Tlk_qgeZPzpm0p1ZS_bg5YrVTXicNmOfXe2ZJR9AgQEXiKc1kjmEvAV9_P8J_fqCQHZXJzQXFG2xHyBGh01268N63GWxszTGGOuxLmjMKMbmI1oJtQUWntlglKDAOCVNYplJDfNq88jNm9e3iPmp9np1cn5_jyx7eLk6-X2HLNCuZWaym8ZgOVVHlLudJWcU68GJToZNd2TArhpeIO1DBo2fZ00ACi9Uxwyo6aiz13iLAx2xQmSLcmQjD3HzGtTJ0p2NEZq3ugzHutWM-57kDaXgxAlWZOSOkr68uetV36yQ22HiTB-Az6vDOHtVnFayMJF4zpCvj0AEjx1-JyMVPI1o0jzC4u2VBCKKn7clKlH_-TbuKS5nqqqmo7pepUOyDZq2yKOSfnH4chrdkFxOwDYmpAzC4g5q56Pjzd4tHxLxHsL8Tdt_U</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2108777939</pqid></control><display><type>article</type><title>Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Szeremeta, Anna ; Jura-Półtorak, Agnieszka ; Koźma, Ewa Maria ; Głowacki, Andrzej ; Kucharz, Eugeniusz Józef ; Kopeć-Mędrek, Magdalena ; Olczyk, Krystyna</creator><creatorcontrib>Szeremeta, Anna ; Jura-Półtorak, Agnieszka ; Koźma, Ewa Maria ; Głowacki, Andrzej ; Kucharz, Eugeniusz Józef ; Kopeć-Mędrek, Magdalena ; Olczyk, Krystyna</creatorcontrib><description>In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed.
Plasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits.
Total sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels.
Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.</description><identifier>ISSN: 1478-6362</identifier><identifier>ISSN: 1478-6354</identifier><identifier>EISSN: 1478-6362</identifier><identifier>DOI: 10.1186/s13075-018-1711-z</identifier><identifier>PMID: 30227885</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject><![CDATA[Acids ; Adalimumab - administration & dosage ; Adult ; Antirheumatic Agents - administration & dosage ; Arthritis ; Arthritis, Rheumatoid - blood ; Arthritis, Rheumatoid - drug therapy ; Biomarkers - blood ; Certolizumab Pegol - administration & dosage ; Cytokines ; Diabetes ; Drug Therapy, Combination ; Etanercept - administration & dosage ; Extracellular matrix ; Female ; Glycosaminoglycans ; Glycosaminoglycans - blood ; Health risk assessment ; Humans ; Hyaluronic acid ; Inflammation ; Keratan sulfate ; Metabolism ; Metabolites ; Methotrexate - administration & dosage ; Middle Aged ; Monoclonal antibodies ; Oxidative stress ; Pathogenesis ; Rheumatoid arthritis ; Time Factors ; TNF inhibitors ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - metabolism ; Tumor necrosis factor-alpha inhibitors ; Tumor necrosis factor-TNF ; Womens health]]></subject><ispartof>Arthritis research & therapy, 2018-09, Vol.20 (1), p.211-211, Article 211</ispartof><rights>Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423</citedby><cites>FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145339/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2108777939?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30227885$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szeremeta, Anna</creatorcontrib><creatorcontrib>Jura-Półtorak, Agnieszka</creatorcontrib><creatorcontrib>Koźma, Ewa Maria</creatorcontrib><creatorcontrib>Głowacki, Andrzej</creatorcontrib><creatorcontrib>Kucharz, Eugeniusz Józef</creatorcontrib><creatorcontrib>Kopeć-Mędrek, Magdalena</creatorcontrib><creatorcontrib>Olczyk, Krystyna</creatorcontrib><title>Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis</title><title>Arthritis research & therapy</title><addtitle>Arthritis Res Ther</addtitle><description>In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed.
Plasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits.
Total sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels.
Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.</description><subject>Acids</subject><subject>Adalimumab - administration & dosage</subject><subject>Adult</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Arthritis</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biomarkers - blood</subject><subject>Certolizumab Pegol - administration & dosage</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>Drug Therapy, Combination</subject><subject>Etanercept - administration & dosage</subject><subject>Extracellular matrix</subject><subject>Female</subject><subject>Glycosaminoglycans</subject><subject>Glycosaminoglycans - blood</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hyaluronic acid</subject><subject>Inflammation</subject><subject>Keratan sulfate</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Methotrexate - administration & dosage</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Oxidative stress</subject><subject>Pathogenesis</subject><subject>Rheumatoid arthritis</subject><subject>Time Factors</subject><subject>TNF inhibitors</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Tumor necrosis factor-alpha inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><subject>Womens health</subject><issn>1478-6362</issn><issn>1478-6354</issn><issn>1478-6362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1uFDEQhVsIRELgAGyQJTZsHNr_7Q0SihISKYJNWFvVbnvGo-72YLsTJbfiIpwJTyZECSuXXO99qiq9pnlP2mNCOvk5E9YqgVvSYaIIwXcvmkPCVYclk_Tlk_qgeZPzpm0p1ZS_bg5YrVTXicNmOfXe2ZJR9AgQEXiKc1kjmEvAV9_P8J_fqCQHZXJzQXFG2xHyBGh01268N63GWxszTGGOuxLmjMKMbmI1oJtQUWntlglKDAOCVNYplJDfNq88jNm9e3iPmp9np1cn5_jyx7eLk6-X2HLNCuZWaym8ZgOVVHlLudJWcU68GJToZNd2TArhpeIO1DBo2fZ00ACi9Uxwyo6aiz13iLAx2xQmSLcmQjD3HzGtTJ0p2NEZq3ugzHutWM-57kDaXgxAlWZOSOkr68uetV36yQ22HiTB-Az6vDOHtVnFayMJF4zpCvj0AEjx1-JyMVPI1o0jzC4u2VBCKKn7clKlH_-TbuKS5nqqqmo7pepUOyDZq2yKOSfnH4chrdkFxOwDYmpAzC4g5q56Pjzd4tHxLxHsL8Tdt_U</recordid><startdate>20180918</startdate><enddate>20180918</enddate><creator>Szeremeta, Anna</creator><creator>Jura-Półtorak, Agnieszka</creator><creator>Koźma, Ewa Maria</creator><creator>Głowacki, Andrzej</creator><creator>Kucharz, Eugeniusz Józef</creator><creator>Kopeć-Mędrek, Magdalena</creator><creator>Olczyk, Krystyna</creator><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180918</creationdate><title>Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis</title><author>Szeremeta, Anna ; Jura-Półtorak, Agnieszka ; Koźma, Ewa Maria ; Głowacki, Andrzej ; Kucharz, Eugeniusz Józef ; Kopeć-Mędrek, Magdalena ; Olczyk, Krystyna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acids</topic><topic>Adalimumab - administration & dosage</topic><topic>Adult</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Arthritis</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biomarkers - blood</topic><topic>Certolizumab Pegol - administration & dosage</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>Drug Therapy, Combination</topic><topic>Etanercept - administration & dosage</topic><topic>Extracellular matrix</topic><topic>Female</topic><topic>Glycosaminoglycans</topic><topic>Glycosaminoglycans - blood</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hyaluronic acid</topic><topic>Inflammation</topic><topic>Keratan sulfate</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Methotrexate - administration & dosage</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Oxidative stress</topic><topic>Pathogenesis</topic><topic>Rheumatoid arthritis</topic><topic>Time Factors</topic><topic>TNF inhibitors</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Tumor necrosis factor-alpha inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szeremeta, Anna</creatorcontrib><creatorcontrib>Jura-Półtorak, Agnieszka</creatorcontrib><creatorcontrib>Koźma, Ewa Maria</creatorcontrib><creatorcontrib>Głowacki, Andrzej</creatorcontrib><creatorcontrib>Kucharz, Eugeniusz Józef</creatorcontrib><creatorcontrib>Kopeć-Mędrek, Magdalena</creatorcontrib><creatorcontrib>Olczyk, Krystyna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Arthritis research & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szeremeta, Anna</au><au>Jura-Półtorak, Agnieszka</au><au>Koźma, Ewa Maria</au><au>Głowacki, Andrzej</au><au>Kucharz, Eugeniusz Józef</au><au>Kopeć-Mędrek, Magdalena</au><au>Olczyk, Krystyna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis</atitle><jtitle>Arthritis research & therapy</jtitle><addtitle>Arthritis Res Ther</addtitle><date>2018-09-18</date><risdate>2018</risdate><volume>20</volume><issue>1</issue><spage>211</spage><epage>211</epage><pages>211-211</pages><artnum>211</artnum><issn>1478-6362</issn><issn>1478-6354</issn><eissn>1478-6362</eissn><abstract>In this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed.
Plasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits.
Total sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels.
Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>30227885</pmid><doi>10.1186/s13075-018-1711-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1478-6362 |
ispartof | Arthritis research & therapy, 2018-09, Vol.20 (1), p.211-211, Article 211 |
issn | 1478-6362 1478-6354 1478-6362 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_c9ba23ff973b4498a6cb5da2793e566f |
source | Publicly Available Content Database; PubMed Central |
subjects | Acids Adalimumab - administration & dosage Adult Antirheumatic Agents - administration & dosage Arthritis Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - drug therapy Biomarkers - blood Certolizumab Pegol - administration & dosage Cytokines Diabetes Drug Therapy, Combination Etanercept - administration & dosage Extracellular matrix Female Glycosaminoglycans Glycosaminoglycans - blood Health risk assessment Humans Hyaluronic acid Inflammation Keratan sulfate Metabolism Metabolites Methotrexate - administration & dosage Middle Aged Monoclonal antibodies Oxidative stress Pathogenesis Rheumatoid arthritis Time Factors TNF inhibitors Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - metabolism Tumor necrosis factor-alpha inhibitors Tumor necrosis factor-TNF Womens health |
title | Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T09%3A00%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20a%2015-month%20anti-TNF-%CE%B1%20treatment%20on%20plasma%20levels%20of%20glycosaminoglycans%20in%20women%20with%20rheumatoid%20arthritis&rft.jtitle=Arthritis%20research%20&%20therapy&rft.au=Szeremeta,%20Anna&rft.date=2018-09-18&rft.volume=20&rft.issue=1&rft.spage=211&rft.epage=211&rft.pages=211-211&rft.artnum=211&rft.issn=1478-6362&rft.eissn=1478-6362&rft_id=info:doi/10.1186/s13075-018-1711-z&rft_dat=%3Cproquest_doaj_%3E2108777939%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-4c9965f93d2627fc2479c7441f5d75868083655f674ea7dd960b2d9aa50f35423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2108777939&rft_id=info:pmid/30227885&rfr_iscdi=true |